233 related articles for article (PubMed ID: 21625469)
1. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
[TBL] [Abstract][Full Text] [Related]
2. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
3. Loss of central auditory processing in a mouse model of Canavan disease.
von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
5. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
8. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
9. Feline Spongy Encephalopathy With a Mutation in the
Takaichi Y; Chambers JK; Shiroma-Kohyama M; Haritani M; Une Y; Yamato O; Nakayama H; Uchida K
Vet Pathol; 2021 Jul; 58(4):705-712. PubMed ID: 33779415
[TBL] [Abstract][Full Text] [Related]
10. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
11. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
12. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
13. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
George Priya Doss C; Zayed H
Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
[TBL] [Abstract][Full Text] [Related]
14. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
[TBL] [Abstract][Full Text] [Related]
15. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
16. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
Kumar S; Biancotti JC; Matalon R; de Vellis J
J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of, and pharmacological treatment for, Canavan disease.
Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
[TBL] [Abstract][Full Text] [Related]
18. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
Kaul R; Balamurugan K; Gao GP; Matalon R
Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
[TBL] [Abstract][Full Text] [Related]
19. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
20. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]